watch
NPS Pharmaceuticals, Inc.

NPS Pharmaceuticals, Inc.

Sector: Biological Products Except Diagnostic Substances Region: NJ, United States


: | Nasdaq: NPSP


NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a global biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® (U.S.)/Revestive® (EU) 0.05 mg/kg/b (teduglutide [rDNA origin]) for injection for subcutaneous use is approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS has also developed Natpara® (rhPTH [1-84]) for the treatment of hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013. NPS's earlier stage pipeline includes NPSP795, a calcilytic compound with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia (ADH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates.

Investor Calendar

Executives

Francois Nader, MD, President and Chief Executive Officer
Francois Nader, MD, has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharmaceuticals since 2008. During his tenure, Dr. Nader transformed NPS into a leading global biotechnology company focused on pioneering and delivering innovative therapies that transform the lives of patients with rare diseases worldwide. NPS’ lead product, Gattex® (US)/Revestive® (EU) for adult Short Bowel Syndrome, was approved in the US and Europe in 2012. NPS has also developed Natpara® for hypoparathyroidism and submitted its Biologic License Application to the U.S. Food and Drug Administration in October 2013.

Dr. Nader is a 30-year veteran of the healthcare industry. He joined NPS in 2006 as chief medical and commercial officer and was promoted to chief operating officer in 2007. Previously, he was a venture partner at Care Capital. Dr. Nader served on the North America Leadership Team of Aventis and its predecessor companies and held a number of executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Prior, Dr. Nader led the global commercial operations at the Pasteur Vaccines division of Rhone-Poulenc.

Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee. Dr. Nader currently serves as chairman of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. Dr. Nader is a Board member of the Biotechnology Industry Organization (BIO) and the New Jersey Chamber of Commerce. He is also a Director of Trevena, Inc. and Clementia Pharmaceuticals, Inc.
Luke M. Beshar, CPA, Executive Vice President and Chief Financial Officer
Luke Beshar has served as Senior Vice President and Chief Financial Officer of NPS Pharmaceuticals since November 2007. At NPS, Mr. Beshar is responsible for all financial management, investor relations, information technology, technical operations, supply-chain management, facilities, and contracts and outsourcing. Since joining the company in 2007, Mr. Beshar has utilized his 25 years of experience to help transform NPS strategically and financially. During his tenure, NPS has secured over $250 million of new capital. Mr. Beshar has reorganized and built a high-caliber finance team and established a disciplined financial planning and analysis function.

Prior to joining NPS, from December 2002 to November 2007, Mr. Beshar served as executive vice president and chief financial officer of Cambrex Corporation, a global life sciences company. At Cambrex, Mr. Beshar’s accomplishments included raising approximately $600 million of new capital, building a high-performance global finance team and designing and implementing $8 million in cost reductions. From January 2002 to December 2002, he was senior vice president and chief financial officer at Dendrite International, a leading provider of services to the life sciences industry.

Mr. Beshar began his career with Arthur Andersen & Co. in 1980 and is a certified public accountant. Mr. Beshar obtained his BS degree in Accounting and Finance from Michigan State University and is a graduate of The Executive Program at the Darden Graduate School of Business at the University of Virginia.
Paul Firuta, MBA, President, US Commercial Operations
Paul Firuta joined NPS in March 2014 with twenty-three years of industry experience launching and commercializing biologics and pharmaceutical products. Previously, Mr. Firuta served ViroPharma, Inc. from 2008 to 2014 as Vice President and General Manager, Americas. Prior to his term at ViroPharma, he was in several leadership roles with Johnson and Johnson and Lev Pharmaceutical. His responsibilities included National Accounts, Managed Care, and Managed Markets. He also served SmithKline Beecham for nine years in multiple leadership roles in the Managed Care Division.

Mr. Firuta began his career in finance and accounting as an Asset/Liabilities Management Analyst for a large national bank and Internal Auditor for a large national conglomerate, both affording him opportunity to gain early international experience. Mr. Firuta received his bachelor’s degree from King’s College and Masters of Business Administration from St. Joseph’s University.
Robin D. Friedman, Senior Vice President, Human Resources
Robin Friedman joined NPS in March 2014 as the company’s Senior Human Resources Officer with more than 20 years of human resource management experience at leading multi-national pharmaceutical companies. She has substantial expertise in managing all aspects of Human Resources within organizations with strong growth trajectories. Ms. Friedman joined NPS from LifeCell Corporation, a manufacturer and distributor of tissue repair products, where she was senior vice president of human resources and communications and managed an international team responsible for these functions. Previously, she was director of human resources at Johnson & Johnson Pharmaceutical Services where she helped manage a number of important organizational transitions. Ms. Friedman has also held human resources and organizational development positions of increasing responsibility with Biovail and Bristol Myers Squibb and was an external human resources consultant to several organizations including Pharmacia, Novartis, and Columbia Labs. Ms. Friedman received her undergraduate degree from Monmouth College and her master’s degree in counseling and personnel services from The College of New Jersey.
Roger J. Garceau, MD, FAAP, Executive Vice President and Chief Medical Officer
Roger Garceau, MD, joined NPS in December 2008 and brings over 20 years of broad pharmaceutical industry experience to his position. From 2002 to December 2008, Dr. Garceau served in a number of senior leadership positions at sanofi-aventis and most recently was vice president of the new products group. Previously, Dr. Garceau held various positions, including vice president of clinical operations, interim head of North American medical and regulatory affairs, and head of US medical research, where he led a team of over 200 professionals and oversaw the design and execution of over 50 sponsored clinical trials in 5 different therapeutic areas. Prior to his tenure at sanofi-aventis, Dr. Garceau spent 16 years with Pharmacia Corporation in global development and medical affairs, where he successfully contributed to a number of marketing applications. Dr. Garceau is a board-certified pediatrician. He received a Bachelor of Science in Biology from Fairfield University in Fairfield, Connecticut and his Doctorate of Medicine from the University of Massachusetts Medical School. He is a Fellow of the American Academy of Pediatrics.
Susan E. Graf, RPh, Vice President, Corporate Development & Strategy
Susan Graf joined NPS in May 2013 with nearly 20 years of broad industry experience in global business development and commercial operations. Before she joined NPS, Ms. Graf spent 17 years at Roche, most recently as global head, commercial assessment and due diligence for Roche Partnering.

She began her career at Roche in technical operations and then moved to the commercial side taking on roles in sales and marketing research. Ms. Graf later served as director of global business development, director of US marketing and global head of strategic evaluation where she was responsible for product licensing and acquisition during the integration of Genentech into the Roche organization.

Ms. Graf is a licensed pharmacist and received her Bachelor of Science degree in Pharmacy from Purdue University and her Master of Business Administration degree from the Leonard N. Stern School of Business at New York University.
Christine Mikail, JD, Senior Vice President, Legal Affairs, General Counsel and Secretary
Christine Mikail joined NPS in March 2014 with extensive experience in public company representation, business development and pharmaceutical law. In her role, she is responsible for overseeing all global legal and compliance matters. Before joining NPS, Ms. Mikail was executive vice president, corporate development, as well as general counsel, chief compliance officer and corporate secretary at Dendreon Corporation. While at Dendreon, she built and led a bi-coastal legal and compliance team, as well as a business development team. Previously, she held senior corporate development and legal positions with Savient Pharmaceuticals, ImClone Systems and Eli Lilly. Ms. Mikail began her legal career working at several prominent law firms where she counseled on corporate and securities law, regulatory, licensing, financings and M&A activities on behalf of public and private companies. She received her bachelor’s degree cum laude from Rutgers University and her Juris Doctor degree from Fordham University School of Law.
Eric Pauwels, Senior Vice President & President, NPS Pharma International
Eric Pauwels joined NPS in September 2011 as Senior Vice President and Chief Commercial Officer and was promoted to President, NPS Pharma International in 2014. Mr. Pauwels has more than 25 years of healthcare experience in biopharmaceuticals and medical devices.

Over the course of his career, he has launched more than 20 biopharmaceutical products in the areas of rare genetic diseases, cardiovascular disease, urology, gynecology, and CNS/neuroscience. Most recently, Mr. Pauwels was Senior Vice President and Chief Marketing Officer at Accuray Incorporated, a premier radiation oncology company with over 1000 employees worldwide.

From 2005 to 2010, Mr. Pauwels served as chief commercial officer at Shire Human Genetic Therapies (Shire HGT), where he led all commercial functions and launched four orphan drugs. Previously, Mr. Pauwels held the position of vice president of global strategic marketing for both the men's health and cardiovascular disease practices of Bayer Healthcare Pharmaceuticals. Mr. Pauwels also brings more than 15 years of alliance-management experience to NPS, having managed collaborations with companies such as Abbott, Centocor, Dianippon-Sumitomo, Genzyme, GlaxoSmithKline, Organon, and Takeda. Mr. Pauwels earned his Bachelor of Science degree from California State Polytechnic University in Pomona, California.
Joseph J. Rogus, PE, Senior Vice President, Global Technical Operations and Supply Chain Management
Joseph Rogus joined NPS in April 2007. With over 35 years of pharmaceutical industry experience, Mr. Rogus has a wealth of knowledge of pharmaceutical and technology development through commercialization and marketed product support in the global environment. Prior to joining NPS, Mr. Rogus served as vice president of pharmaceutical development at Chugai Pharma USA. Previously he served as senior vice president of technical operations at Advancis Pharmaceutical Corporation. Before his tenure at Advancis, Mr. Rogus spent over 30 years with Schering-Plough Research Institute where he served as vice president of pharmaceutical product optimization and clinical supplies management. Mr. Rogus obtained his Bachelor of Science in Chemical Engineering from Newark College of Engineering and his Master of Science in Chemical Engineering from the New Jersey Institute of Technology.

News & Analysis